A 28-year-old woman from Mumbai presents with a 3-month history of palpitations, tremor, heat intolerance, and weight loss despite good appetite. On examination, she has a diffuse thyroid enlargement, exophthalmos, and a resting heart rate of 118 bpm. TSH is <0.01 mIU/L, free T4 is 45 pmol/L (normal 10–20), and free T3 is 12 pmol/L (normal 3.5–8). She is started on antithyroid therapy. Which of the following drugs would be most appropriate as the initial choice, and why?

Explanation

## Clinical Scenario Analysis This patient presents with classic **Graves' disease** (diffuse goiter, exophthalmos, tachycardia, elevated free T4 and T3, suppressed TSH). The question asks for the **most appropriate initial antithyroid drug**. ## Antithyroid Drug Comparison | Feature | Methimazole | Propylthiouracil (PTU) | |---------|-------------|------------------------| | **Dosing frequency** | Once daily (longer half-life 4–6 h) | Three times daily (half-life 1–2 h) | | **T4 → T3 conversion block** | No | Yes (peripheral) | | **Agranulocytosis risk** | ~0.01% | ~0.3% | | **Hepatotoxicity** | Very rare, mild | Rare but potentially fulminant/fatal | | **Preferred in pregnancy** | 2nd/3rd trimester | 1st trimester only | | **First-line for most adults** | **Yes** | No (reserved for specific indications) | ## Why Methimazole (Option C) Is Correct **Key Point:** Per current ATA (American Thyroid Association) guidelines and standard pharmacology texts (KD Tripathi 8e, Harrison's 21e), **methimazole is the first-line antithyroid drug for Graves' disease in non-pregnant adults** because: 1. **Once-daily dosing** (longer half-life of 4–6 hours) → superior compliance compared to PTU's thrice-daily regimen 2. **Lower risk of agranulocytosis** (~0.01% vs ~0.3% with PTU) 3. **No risk of fulminant hepatic necrosis** — PTU carries a rare but potentially fatal hepatotoxicity risk (FDA black-box warning issued 2010), making it unsuitable as routine first-line therapy 4. **Equivalent efficacy** for achieving euthyroid state in non-storm presentations 5. This patient is a 28-year-old woman with severe but **non-storm** thyrotoxicosis — there is no indication to prefer PTU over methimazole **High-Yield:** PTU is reserved for: (1) first trimester of pregnancy, (2) thyroid storm (where peripheral T4→T3 blockade is critical), (3) methimazole allergy/intolerance. This patient does not fall into any of these categories. **Clinical Pearl:** Propranolol (option A) is an essential **adjunctive agent** to control adrenergic symptoms (tachycardia, tremor, anxiety) but does NOT reduce thyroid hormone synthesis. It should be added alongside methimazole, not used alone. ## Why Each Distractor Is Wrong **Propranolol alone (Option A):** Propranolol is adjunctive only — it controls symptoms via beta-blockade but does not reduce thyroid hormone synthesis or secretion. It must always be combined with a definitive antithyroid drug. **Iodine solution/Lugol's iodine (Option B):** Never used as monotherapy. Iodine inhibits hormone release acutely (Wolff-Chaikoff effect) but causes "escape" after 10–14 days. It is reserved for thyroid storm or pre-operative preparation, always given *after* starting PTU or methimazole to prevent iodine-induced worsening. **PTU 100 mg TDS (Option D):** While PTU does block peripheral T4→T3 conversion, this advantage is clinically significant only in **thyroid storm** or **first-trimester pregnancy**. For routine Graves' disease management, PTU's thrice-daily dosing, higher agranulocytosis risk, and risk of fulminant hepatotoxicity make it inferior to methimazole as initial therapy. The ATA guidelines (2016, updated 2022) explicitly recommend methimazole over PTU for most adults. ## Clinical Approach Summary - **Non-pregnant adult with Graves' disease (non-storm):** Methimazole 10–30 mg/day + Propranolol for symptom control - **Thyroid storm:** PTU 200 mg every 4–6 h (peripheral conversion blockade critical) + Lugol's iodine (given ≥1 h after PTU) + Propranolol + Glucocorticoids - **First-trimester pregnancy:** PTU preferred (methimazole embryopathy risk) [cite: KD Tripathi 8e Ch 32; Harrison's Principles of Internal Medicine 21e Ch 376; ATA Guidelines for Hyperthyroidism 2016]